Compare CPIX & BTCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPIX | BTCS |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | United States | United States |
| Employees | 91 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.6M | 75.4M |
| IPO Year | 2007 | 2008 |
| Metric | CPIX | BTCS |
|---|---|---|
| Price | $4.81 | $1.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 156.6K | ★ 960.4K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | ★ 3.03% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.48 |
| Revenue | ★ $42,010,949.00 | $4,073,518.00 |
| Revenue This Year | N/A | $248.05 |
| Revenue Next Year | N/A | $41.01 |
| P/E Ratio | ★ N/A | $1.10 |
| Revenue Growth | 16.75 | ★ 204.08 |
| 52 Week Low | $1.85 | $1.27 |
| 52 Week High | $7.25 | $8.49 |
| Indicator | CPIX | BTCS |
|---|---|---|
| Relative Strength Index (RSI) | 71.91 | 36.43 |
| Support Level | $4.81 | N/A |
| Resistance Level | $5.37 | $3.13 |
| Average True Range (ATR) | 0.22 | 0.14 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 94.38 | 31.17 |
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
BTCS Inc. ("BTCS" or the "Company"), short for Blockchain Technology Consensus Solutions, is a U.S.-based Ethereum-first blockchain technology company committed to driving scalable revenue and ETH accumulation through its hallmark strategy, the DeFi/TradFi Accretion Flywheel, an integrated approach to capital formation and blockchain infrastructure. By combining decentralized finance ("DeFi") and traditional finance ("TradFi") mechanisms with its blockchain infrastructure operations, comprising NodeOps (staking) and Builder+ (block building), BTCS offers one of the most sophisticated opportunities for leveraged ETH exposure, driven by scalable revenue generation and a yield-focused ETH accumulation strategy. Discover how BTCS offers operational and financial leveraged exposure to Ethereum through the public markets at www.btcs.com.